Diagnosing the Future: How Pro Medicus Is Redefining Enterprise Imaging Globally
A tech-driven leader with high-margin growth, expanding U.S. footprint, and a pipeline backed by execution
Key Takeaways:
- Net profit rose 42.7% to $51.7M, with revenue up 31.1% to $97.2M for the half-year.
- PME secured over $485M in new contracts across North America, including Trinity Health and LucidHealth.
- Maintained 72% EBIT margins while remaining debt-free with $182.3M in cash and financial assets.
- Strengthened AI and cardiology roadmap through UCSF research collaboration and new cardiac echo contracts.
The PME Model: Scaling Tech Where It Matters Most
Pro Medicus (ASX: PME) isn’t just supplying imaging software - it’s replacing legacy infrastructure with a full-stack cloud-native system built for scale. Through its Visage 7 platform, PME is delivering speed, efficiency, and high-volume throughput to some of the largest academic hospitals and private teleradiology groups in North America. Recent deployments at Baylor Scott & White, completed in just 11 months, reinforce their reputation for rapid implementation often cited by clients as a key differentiator.
With a transaction-based revenue model and over 60% of healthcare IT spend concentrated in the U.S., PME’s execution-led expansion is unlocking deeper penetration across integrated delivery networks (IDNs), academic centers, and private groups. The $330M Trinity Health contract alone pushed PME’s U.S. market share above 8%, with room for more.
Innovation That Doesn’t Just Sound Good - It executes
- AI in action: PME’s Visage AI Accelerator is now in a multi-year collaboration with UCSF to drive AI tool development toward commercial use.
- Cardiology breakthrough: Signed its first commercial contract for a cardiac echo package marking entry into new diagnostic areas like cardiology and neurology.
- R&D advantage: Releases 2–3 major Visage 7 updates annually, boosting features and client stickiness.
- Cloud-first traction: Ongoing shift to cloud-based workflows continues to position PME as mission-critical in imaging IT.
Pro Medicus continues to prove that precision, performance, and patient-focused technology can scale setting the pace for enterprise imaging globally.
Breathing Easy: ResMed’s Steady Expansion in Health-Tech and Home Care
A global sleep-tech leader scaling smart, capital-efficient growth across both hardware and cloud platforms.
Key Takeaways:
- Net income surged 21% YoY to $365 million for Q3 FY25, with total revenue rising 7.9% to $1.29 billion.
- U.S. and Latin America drove device sales to $676M, while residential care software crossed $161M.
- ResMed generated $1.2B in operating cash flow, ending the quarter with $932M in cash and equivalents.
- Expanded gross margin and continued disciplined R&D investment across both core and SaaS businesses.
Two Engines, One Smart Strategy
- ResMed’s not just selling sleep tech it’s scaling a connected care platform. Hardware demand stays strong in key global markets, while its SaaS tools for home care providers keep gaining traction. Together, they create a flywheel of recurring growth.
- The real win? They’re doing it without overextending. Lean operations, steady innovation, and smart capital moves like buybacks and debt reduction keep the engine humming.
- The playbook’s clear: align products that solve real problems, stay efficient, and grow where it matters.
Financial Flexibility + Market Fit = Durable Advantage
The fundamentals are clear. ResMed generated over $1.2B in operating cash flow in just nine months and declared $0.53 per share in quarterly dividends, while maintaining strong reinvestment in future tech. Inventory and accounts receivable were tightly managed, and cash on hand nearly quadrupled compared to the start of the year.
This kind of disciplined execution is what keeps RMD well positioned in a fragmented global market. With sleep disorder awareness rising and SaaS penetration in elder care still low, ResMed’s platform continues to unlock recurring, high-margin growth from both reimbursement-backed devices and enterprise software.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
